<DOC>
	<DOCNO>NCT01399645</DOCNO>
	<brief_summary>This study conduct test hypothesis type 2 diabetic adult fatty liver resistant metformin , treatment liraglutide combination metformin cause absolute reduction liver fat superior insulin-metformin treatment within 3-month period , measure magnetic resonance imaging ( MRI ) .</brief_summary>
	<brief_title>Study Liraglutide Versus Insulin Liver Fat Fraction Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Background : Non-alcoholic fatty liver disease ( NAFLD ) identify 70 % patient type 2 diabetes . Insulin introduce point treatment diabetes , potentially lipogenic . Preliminary study show conflict result impact insulin fatty liver . Objectives : This study conduct test hypothesis type 2 diabetic adult NAFLD resistant metformin , treatment liraglutide combination metformin cause absolute reduction liver fat superior insulin-metformin treatment within 3-month period , measure vivo MRI MRS. Design : This prospective , open label , randomize parallel trial evaluate whether 12 week treatment ) liraglutide-metformin improve steatosis type 2 diabetic adult NAFLD compare treatment b ) insulin-metformin . Before post-treatment MRI MRS read blindly quantification steatosis . The primary outcome measure define improvement steatosis 5 % treatment 2 treatment group . Methods : Thirty-six patient randomize either study group . After baseline metabolic measurement blood sampling , transient ultrasound elastography , MRI MRS , subject give metformin start dose 500 mg one tablet twice daily . In addition , patient randomize receive either liraglutide ( 0.6 - 1.8 mg subcutaneous per day ) insulin glargine initial bedtime start dose 10 IU duration 3 month . Expected result : The result study provide preliminary data large scale study compare 2 therapeutic regimen establish utility MRI MRS monitor medical treatment diabetic patient fatty liver disease .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Are 18 y.o . old screening ( first visit ) , Are ambulatory , Are know type 2 diabetes criteria failure metformin monotherapy , metforminsulfonylurea , metforminrepaglinide combine therapy define HbA1C â‰¥6.5 , Abdominal girth &gt; 94 cm men &gt; 80 cm woman , Understand French English instruction , Able comprehend willingness provide voluntary consent . Have contraindication MRI ( metallic implant , pacemaker claustrophobia ) , Have type 1 diabetes episodes ketoacidosis , Have major debilitate disease include malignant disorder , Have , within last 6 month , evidence significant heart disease stroke , include myocardial infarction , unstable angina , coronary bypass and/or percutaneous transluminal coronary angioplasty ( PTCA ) , congestive heart failure ( New York Heart Association Class IIIIV ) , severe ischemic disease , Patients receive insulin within 3 month prior screen , Have serum creatine &gt; 150 mmol/L estimate GFR &lt; 30 mL/min , Women seek pregnancy , Have history chronic liver disease NAFLD , include HBV HCV infection , hemochromatosis , Wilson 's disease , alpha1antitrypsin deficiency , autoimmune hepatitis , Current previous use oral injectable corticosteroid , Have excessive alcohol intake , define daily limit 30 g ( 3 drink ) men 20 g ( 2 drink ) woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Randomized trial</keyword>
	<keyword>Open label</keyword>
	<keyword>Pilot study</keyword>
	<keyword>Single center</keyword>
</DOC>